On January 15, 2024, we reached a significant milestone when the final patient completed our initial feasibility study on Dorsal Genital Nerve Stimulation (DGNS) for treating Overactive Bladder (OAB) and Bowel Disorder (BD). Our collaboration with the partner hospitals in Aarhus, Odense, and Herlev began in April 2022. This initial study focused on our patented Patch Electrode and its use with our external neurostimulator, UCon. The study has now been completed, and 40 patients with OAB and 40 patients with BD were included.

The preliminary results have been encouraging, demonstrating the potential of DGNS when utilized with our Patch Electrode and UCon neurostimulator. We presented positive partial results for initial OAB patients at the International Continence Society (ICS) 2023 conference in Toronto and BD patients at the European Society of Coloproctology (ESCP) 2023 in Vilnius. We are currently finalizing the data analysis for the complete study, which we intend to present at future meetings and submit for publication.

We are extremely pleased with the collaboration we have enjoyed with our clinical partners and look forward to initiating our pivotal study for the CE mark in Q2 of 2024.